| abstract |
The present invention provides fibronectin-based binding molecules, and methods for introducing donor CDRs into fibronectin-based binding scaffolds, particularly Fn3. Fibronectin-based binding molecules of the invention can be further conjugated to other moieties such as Fc, anti-FcRn, HSA, anti-HSA, and PEG for improved half-life and stability, particularly in mammalian cells. have. The invention also provides a method of screening the molecule for binding to a target antigen, and a method for preparing and purifying a candidate binder. |